November 16, 2010 (CHAPEL HILL, NC) Thought Leader Select, a North Carolina firm dedicated to delivering the most accurate and effective key opinion leader (KOL) profiling research for the biopharmaceutical industry, announces the launch of a drug reimbursement project for a top-10 US pharmaceutical company.
With a new drug for treating coagulation coming to the market in 2011, the client contracted Thought Leader Select to find advisors for reimbursement for the new drug. Thought Leader Select is helping the client company by finding the most qualified market access advisors throughout the United States. These key opinion leaders (KOLs) range from pharmacy directors to translational benefit influencers.
The payer KOLs will be found from across the United States through Thought Leader Select’s extensive databases. Through a deep profiling methodology based on 15 categories, ranging from area of expertise to publications, Thought Leader Select will understand the key opinion leaders’ skills and experiences in the area of coagulation.
The role of the customized group of KOLs will be to advise on what the pharmaceutical company needs to accomplish with various private and public formularies to successfully gain reimbursement well in advance of introduction into market.
At project delivery, Thought Leader Select will showcase the market access leaders’ profiles in its proprietary database, Thought Leader Index, according to Neil Mellor, business development consultant. “This database allows users to match the skills and experiences of the KOLs to the respective reimbursement activities needed by the company,” stated Mellor. “With Index, our client is empowered with a user-friendly database for the best reimbursement strategy and obtaining market access.”
About Thought Leader Select
Thought Leader Select serves the biopharmaceutical and healthcare industries, as well as the medical community at large by assessing medical experts (known as “thought leaders” and “key opinion leaders”) within a host of therapeutic areas such as diabetes, oncology, and neurology.
Over two dozen of the top 50 global biopharmaceutical and healthcare companies count on our expertise when seeking to launch new medications for better public health, ensuring that they are collaborating with the right medical professionals for the right reasons—their skills and experiences.Media Contact: Brian Castle Director of Global Marketing and Client Relations 919-360-9690